← All stocks

Enliven Therapeutics, Inc.

ELVN Net selling
CIK 0001672619 #1481 in the set updated 22 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$76.81M
$8.93M on a plan · $15.90M straight out of an exercise
Sold at will
$51.98M
7 of 81 sales
Net
−$76.81M
−$51.98M against sales at will

By person

10 insiders · 83 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$51.68M (6)
−$51.68M
6,555,102
8.95%
$337.47M
−14.8%
Derynck Mika K
Director
$9.56M (1) scheduled
−$9.56M
0
0.0000%
$0.00
Collins Helen Louise
CHIEF MEDICAL OFFICER
$5.39M (24) scheduled
−$5.39M
25,000
0.0341%
$1.29M
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
$4.91M (13) scheduled
−$4.91M
758,938
1.04%
$39.07M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
$1.74M (7) scheduled
−$1.74M
235,011
0.3207%
$12.10M
−31.7%
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$1.60M (15) scheduled
−$1.60M
38,000
0.0519%
$1.96M
Kunkel Lori Anne
Director
$850.25K (5) scheduled
−$850.25K
41,884
0.0572%
$2.16M
−8.8%
Kintz Samuel
PRESIDENT AND CEO
$669.70K (4) scheduled
−$669.70K
890,392
1.22%
$45.84M
−15.0%
Heyman Richard A.
Director
$413.38K (6) scheduled
−$413.38K
146,320
0.1997%
$7.53M
−13.4%
Ballal Rahul D.
Director
22,341
0.0305%
$1.15M
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
46,776
$45.00
$2.10M
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
787,024
$45.38
$35.72M
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
1,477
$45.00
$66.47K
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
24,846
$45.38
$1.13M
ORBIMED ADVISORS LLC
15 Jun 2026
10% owner
Sell indirect
272,322
$45.02
$12.26M
ORBIMED ADVISORS LLC
15 Jun 2026
10% owner
Sell indirect
9,086
$45.02
$409.05K
Hohl Benjamin
6 Mar 2026
CHIEF FINANCIAL OFFICER
Sell
10,000
$29.58
$295.84K

What was left out

Form 4 filings counted 56
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 37
Sales straight out of an exercise 37
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 450,825
History held since 16 Mar 2020